ACY-775

• UNSPSC Description:

  ACY-775 is a potent and selective inhibitor of the of histone deacetylase 6 (HDAC6) with an IC50 of 7.5?nM[1][2]. ACY775 also inhibits metallo-β-lactamase domain-containing protein?2 (MBLAC2)[3].

• Target Antigen:

  HDAC

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Epigenetics

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Neurological Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/ACY-775.html

• Purity:

  99.69

• Solubility:

  DMSO : 25 mg/mL (ultrasonic)

• Smiles:

  O=C(NO)C(C=N1)=CN=C1NC2(CCCCC2)C3=CC=CC(F)=C3

• Molecular Weight:

  330.36

• References & Citations:

  [1]Veronick Benoy, et al. Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease. Neurotherapeutics. 2017 Apr; 14(2): 417-428.|[2]Jeanine Jochems et al. Antidepressant-Like Properties of Novel HDAC6-Selective Inhibitors with Improved Brain Bioavailability. Neuropsychopharmacology. 2014 Jan; 39(2): 389-400.|[3]Severin Lechner, et al. Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target. Nat Chem Biol. 2022 Apr 28.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1375466-18-4